Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Nicoletta Colombo,Coraline Dubot,Domenica Lorusso,M Valeria Caceres,Kosei Hasegawa,Ronnie Shapira-Frommer,Krishnansu S Tewari,Pamela Salman, Edwin Hoyos Usta,Eduardo Yañez,Mahmut Gümüş,Mivael Olivera Hurtado de Mendoza,Vanessa Samouëlian,Vincent Castonguay,Alexander Arkhipov,Sarper Toker,Kan Li,Stephen M Keefe,Bradley J Monk

OBSTETRICAL & GYNECOLOGICAL SURVEY（2022）

引用 298|浏览41

暂无评分

摘要

Progression-free and overall survival were significantly longer with pembrolizumab than with placebo among patients with persistent, recurrent, or metastatic cervical cancer who were also receiving chemotherapy with or without bevacizumab. (Funded by Merck Sharp and Dohme; KEYNOTE-826 ClinicalTrials.gov number, NCT03635567.).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要